SCHEMBL803559

SCHEMBL803559

Cc1cc(N2CCC(N(C)C(=O)OCc3ccccc3)CC2)nc(N(C)C)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.49
SIGMAR1 Q99720 2/20 0.46
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CCR5 P51681 1/20 0.44
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
NAPEPLD Q6IQ20 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL785081 0.90 SIGMAR1 (0.47) GBA1SIGMAR1ALDH1A1MEN1LMNA
SCHEMBL785112 0.87 SIGMAR1 (0.45) GBA1SIGMAR1ALDH1A1MEN1LMNA
SCHEMBL803772 0.86 SIGMAR1 (0.47) SIGMAR1CCR5NAPEPLDHTR1ACHRM5
SCHEMBL786082 0.79 GBA1 (0.47) GBA1ALDH1A1LMNASMN1; SMN2GAA
SCHEMBL784864 0.78 CCR5 (0.51) ALDH1A1MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL803806 0.78 SIGMAR1 (0.46) SIGMAR1CCR5HTR1ACHRM5ADRA2A
SCHEMBL14331974 0.76 SIGMAR1 (0.47) SIGMAR1ALDH1A1LMNASMN1; SMN2CCR5
SCHEMBL803481 0.76 SIGMAR1 (0.50) GBA1SIGMAR1CCR5HTR1ACHRM5
SCHEMBL803732 0.76 SIGMAR1 (0.45) SIGMAR1ALDH1A1LMNASMN1; SMN2CCR5
SCHEMBL803974 0.76 SIGMAR1 (0.45) SIGMAR1CCR5HTR1ACHRM5ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 GBA1 849/4885SIGMAR1 369/4885ALDH1A1 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.